PREVALENT integrates essential pre-clinical research platforms ranging from pre-clinical evaluations of drugs, disease modelling using precision animal models, medicinal chemistry, and the assessment of environmental factors to state-of-the-art in silico modelling approaches.

Unique is the conversion of extensive experimental pre-clinical data into in silico interactive models supporting research and pharma communities to efficiently develop novel or improved therapies, foresee adverse effects, explore repurposing possibilities, and to identify long-term environmental impacts.

Our goal is to establish an integrative Research Infrastructure providing highly standardised, large-scale platforms for pre-clinical and environmental evaluations, and to create an in silico portal for virtual gene-drug-environment actions, as a unique global resource underpinning in silico- and environmental medicine and innovative therapeutic developments.

Prevalent Scheme

News & Events

8th September
Variability in Genome Editing Outcomes Challenges for Research Reproducibility and Clinical Safety
Researchers at MRC Harwell, alongside their colleagues at Université de Strasbourg and Great Ormond Street Institute of Child Health, have published a review in Molecular Therapy (https://www.sciencedirect.com/science/article/pii/S1525001620301490?via%3Dihub). The review explores the reliability and challenges of genome editing application in both research and in clinic.
Show detail
All news
September 17 – 18, 2020 | Prague, Czech Republic
2nd CCP Phenogenomics Conference 2020
The first day will be devoted to the theme “From chemistry via preclinical pipeline to therapeutics“, which emphasizes the translation of the basic research into the application. The second day is specifically devoted to CCP’s users and cooperation partners working in the field of immunology, hematology, genetic base of diseases, and neurobiology.
Show detail
All events